Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

被引：1
|
作者：
Harrison, Claire N. [1 ]
Schaap, Nicolaas [2 ]
Vannucchi, Alessandro M. [3 ]
Kiladjian, Jean-Jacques [4 ]
Jourdan, Eric [5 ]
Silver, Richard T. [6 ]
Schouten, Harry C. [7 ]
Passamonti, Francesco [8 ]
Zweegman, Sonja [9 ]
Talpaz, Moshe [10 ]
Verstovsek, Srdan [11 ]
Rose, Shelonitda [12 ]
Tang, Derek [12 ]
Hu, Angela [12 ]
Guo, Shien [13 ]
Liao, Weiqin [13 ]
Brownstein, Carrie [14 ]
Mesa, Ruben A. [15 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Clin Haematol, London, England
[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[3] Univ Florence, AOU Careggi, Florence, Italy
[4] Hop St Louis, Paris, France
[5] Inst Cancerol Gard, Hematol Clin, Nimes, France
[6] Weill Cornell Med Coll, New York, NY USA
[7] Univ Hosp Maastricht, Dept Internal Med Hematol, Maastricht, Netherlands
[8] Univ Insubria, Dept Med & Surg, Varese, Italy
[9] Vrije Univ Amsterdam, Amsterdam UMC, Dept Hematol, Amsterdam, Netherlands
[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[12] Celgene Corp, Summit, NJ USA
[13] Evidera, Waltham, MA USA
[14] Celgene Corp, Summit, NJ USA
[15] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-129386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2207
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies
    Alsinnawi, Mazen
    Cullen, Jennifer
    Hurwitz, Lauren M.
    Levie, Katherine E.
    Burns, John F.
    Rosner, Inger L.
    Brand, Timothy C.
    Stroup, Sean
    Sterbis, Joseph R.
    Rice, Kevin
    Conti, Galen
    Porter, Christopher R.
    CANADIAN JOURNAL OF UROLOGY, 2019, 26 (04) : 9809 - 9820
  • [32] Imetelstat Is Effective Treatment for Patients With Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 14 - 15
  • [33] Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
    Mascarenhas, John
    Komrokji, Rami S.
    Cavo, Michele
    Martino, Bruno
    Niederwieser, Dietger
    Reiter, Andreas
    Scott, Bart L.
    Baer, Maria R.
    Hoffman, Ronald
    Odenike, Olatoyosi
    Bussolari, Jacqueline
    Zhu, Eugene
    Huang, Fei
    Rose, Esther
    Sherman, Laurie
    Dougherty, Souria
    Feller, Faye M.
    Kiladjian, Jean-Jacques
    BLOOD, 2018, 132
  • [34] Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
    El Chaer, Firas
    McCloskey, James
    Rein, Lindsay A. M.
    Brown, Randy A.
    Green, Steven D.
    Pu, Jeffrey J.
    Shirane, Shuichi
    Shimoda, Kazuya
    Ichii, Michiko
    Yuda, Junichiro
    Scandura, Joseph
    Kabir, Sujan
    Foulks, Jason M.
    Mei, Jian
    Yang, Huyuan
    Wade, Mark
    Stapinski, Carl
    Lebedinsky, Claudia
    Rampal, Raajit K.
    BLOOD, 2022, 140
  • [35] Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
    Lehtonen, Miikka
    Sormunen, Jorma
    Hjalm-Eriksson, Marie
    Thellenberg-Karlsson, Camilla
    Huttunen, Teppo
    Ginman, Claes
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2022, 42 (01) : 87 - 92
  • [36] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
    Pardanani, Animesh
    Harrison, Claire N.
    Cortes, Jorge E.
    Cervantes, Francisco
    Mesa, Ruben A.
    Milligan, Donald
    Masszi, Tamas
    Mishchenko, Elena
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Drummond, Mark
    Jurgutis, Mindaugas
    Kuliczkowski, Kazimierz
    Gheorghita, Emanuil
    Passamonti, Francesco
    Neumann, Frank
    Gao, Guozhi
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [37] A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Li, Li
    Pitou, Celine
    Nunes, Fabio P.
    Price, Gregory L.
    Giles, Jennifer L.
    D'Souza, Deborah N.
    Walgren, Richard A.
    Prchal, Josef T.
    LEUKEMIA RESEARCH, 2017, 61 : 89 - 95
  • [38] Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U. K.
    von der Maase, H.
    Brandberg, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis
    Mascarenhas, John O.
    Rampal, Raajit
    El Chaer, Firas
    Gupta, Vikas
    Shimoda, Kazuya
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Bose, Prithviraj
    Scandura, Joseph M.
    Mesa, Ruben
    Rein, Lindsay A. M.
    Yuda, Junichiro
    Ross, David M.
    Devos, Timothy
    Talpaz, Moshe
    Hoffman, Ronald
    Kabir, Sujan
    Li, Zhonggai
    Foulks, Jason M.
    Ansaldo, Karen
    Seki, Masataka
    Peddagali, Vishnu
    Shah, Jatin
    Harrison, Claire
    BLOOD, 2024, 144 : 6629 - 6631
  • [40] Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
    Ajai Chari
    Markus Munder
    Katja Weisel
    Matthew Jenner
    Ceri Bygrave
    Maria Teresa Petrucci
    Mario Boccadoro
    Michele Cavo
    Niels W. C. J. van de Donk
    Mehmet Turgut
    Fatih Demirkan
    Ihsan Karadogan
    Edward Libby
    Robert Kleiman
    Steven Kuppens
    Rajesh Bandekar
    Tobias Neff
    Christoph Heuck
    Ming Qi
    Pamela L. Clemens
    Hartmut Goldschmidt
    Advances in Therapy, 2021, 38 : 1328 - 1341
12345